Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA4 | P22748 | 3/20 | 0.67 |
| ▸ | CA6 | P23280 | 3/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041587 | 0.89 | CA2 (0.70) | CA1CA2CA4CA6PTGS1 | |
| SCHEMBL28060653 | 0.85 | CA1 (0.65) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL3144588 | 0.79 | CA1 (0.57) | CA1CA2CA4CA6PTGS1 | |
| SCHEMBL8065224 | 0.79 | CA1 (0.57) | CA1CA2CA4CA6PTGS1 | |
| SCHEMBL8065454 | 0.79 | CA1 (0.57) | CA1CA2CA4CA6PTGS1 | |
| SCHEMBL15874736 | 0.78 | CA1 (0.56) | CA1CA2CA4CA6PTGS1 | |
| SCHEMBL7372634 | 0.78 | CA1 (0.56) | CA1CA2CA4CA6PTGS1 | |
| SCHEMBL7485547 | 0.78 | CA1 (0.56) | CA1CA2CA4CA6PTGS1 | |
| SCHEMBL30825624 | 0.78 | CA1 (0.56) | CA1CA2CA4CA6PTGS1 | |
| SCHEMBL29169543 | 0.78 | CA1 (0.56) | CA1CA2CA4CA6PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0842161-B1 | 4,5-DIARYL OXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-18 | — | — | EP | disclosed |
| EP-1213285-A2 | 4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-6300344-B1 | FOR THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF ARTERIAL OBSTRUCTION, CEREBROVASCULAR DISEASE, HEPATIC CIRRHOSIS, ARTERIOSCLEROSIS, ISCHEMIC HEART DISEASE, RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, HYPERTENSION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-09 | — | — | US | disclosed |
| US-6245790-B1 | ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL DISORDERS; SKN DISORDERS; BONE DISORDERS; MUSCLE RELAXANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-0989975-A1 | OXAZOLE COMPOUNDS USEFUL AS PGE2 AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| WO-2000016760-A2 | NEW USE OF PROSTAGLANDIN E2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-30 | — | — | WO | disclosed |
| US-5972965-A | USEFUL FOR INHIBITION OF PLATELET AGGREGATION, VASODILATION, ANTIHYPERTENSIVE ACTIVITY AND PROSTAGLANDIN AGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| WO-1998055468-A1 | OXAZOLE COMPOUNDS USEFUL AS PGE2 AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-10 | — | — | WO | disclosed |
| EP-0842161-A1 | 4,5-DIARYL OXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997003973-A1 | 4,5-DIARYL OXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |